Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Immix Biopharma, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 12.14 · gapped above the open, then crossed back over prior close. High/low 12.40 at 8:30 am ET, 11.90 at 10:45 am ET.
109 institutional managers report a position in Immix Biopharma, Inc. worth $580.8M between them, filed on form 13F for the quarter ending 2026-06-30. 17 of them hold 80% of it, the largest being Jupiter Topco LLC at 17.36%.
84 more managers in the register
17 managers hold 80% of the $580.8M institutional base. The other 92 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
via Jupiter Topco LLC, Deep Track Capital, LP, Wellington Management Group LLP +2 more · 17.36% of IMMX, 20.19% of PMN
via Jupiter Topco LLC, Saturn V Capital Management LLC, Wellington Management Group LLP +1 more · 17.36% of IMMX, 21.12% of MNPR
via Jupiter Topco LLC, Eventide Asset Management, LLC, Balyasny Asset Management LLC +2 more · 17.36% of IMMX, 14.11% of OVID
via Jupiter Topco LLC, Deep Track Capital, LP, Marshall Wace LLP +3 more · 17.36% of IMMX, 13.37% of ENTA
via Jupiter Topco LLC, Saturn V Capital Management LLC, Qube Research & Technologies Ltd · 17.36% of IMMX, 14.74% of IVVD
via Jupiter Topco LLC, Marshall Wace LLP, Eventide Asset Management, LLC +5 more · 17.36% of IMMX, 11.12% of RLMD
Managers holding a meaningful stake in IMMX also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.
IMMX (Immix Biopharma, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.